Drug Discovery World

OCTOBER 13, 2022

There was a selection of the technologies we will present including cell-based assays, ion indicator dyes, inhibitors, pharmacokinetic assays, bioisimilars, assay development antibodies, conjugation particles and other reagents for your drug discovery and development pipeline. . Looking forward .

Drugs 52

Drugs In-Vivo In-Vitro Biobanking 52

The Pharma Data

OCTOBER 19, 2020

Diagnostics Update : To-date the FDA has authorized 282 individual EUAs, which include 220 molecular tests, 56 antibody tests and 6 antigen tests. . DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Diagnostics.

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 15, 2023

The first such research dates back to 1891, when William Coley attempted to inject heat-inactivated bacteria to treat osteosarcoma. This is an exciting field of cancer research which involves harnessing the body’s own immune system to target cancerous cells.

Research 52

Research In-Vitro In-Vivo Development 52

The Pharma Data

DECEMBER 2, 2020

Howard Mayer, Ipsen’s head of research and development, called the Fast Track designation for Onivyde “an extension of Ipsen’s focus and contribution” to the oncology landscape. aeruginosa bacteria, instead of killing the bacteria as an antibiotic would aim to do. in Mainland China. in Mainland China.

Drugs 52

Drugs Gene Editing Genome Genomics 52

Drug Discovery World

JULY 18, 2023

Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19. Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g., Herpesviridae, Polyomaviridae, and Papillomaviridae), bacteria (e.g.,

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

OCTOBER 14, 2020

AOP anticipates new opportunities in Austria as a hub for research and business. VBL Therapeutics – The European Patent Office granted a patent to Israel-based VBL’s proprietary investigational anti-MOSPD2 monoclonal antibodies to treat inflammatory conditions. Axol Bioscience – Based in the U.K., Iksuda Therapeutics – U.K.

Clinical Trials 52

Clinical Trials Clinical Trials Manufacturing Trials 52